Latest Headlines

  1. InNexus Announces Discovery Of Novel Protein For AMD Eye Disorder - Will Bypass Needles With Topical Application
    6/29/2010
    InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, recently announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 years of age in
  2. GENFIT Announces Its Development Plan For GFT505
    6/28/2010
    GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces plans to advance the development of GFT505, its leading drug candidate, following the completion of several clinical studies demonstrating its efficacy and safety in different patient populations. In a double-blind, placebo-controlled Phase IIa clinical trial (GFT505-2094) conducted in 47 pre-diabetic patients with elevated
  3. New System Gives Biopharm The Power Of UPLC
    6/28/2010
    Last week, I traveled to the Waters Corporation in Milford, MA, to visit with several members of the the company's team about their new ACQUITY UPLC H-Class Bio System. Considering the company had just released the ACQUITY UPLC H-Class System in January 2010, I wondered why there was a need to release a new version so quickly. I quickly learned that this new system was a version "fit for purpose" for the biopharmaceutical market.
  4. Chemists Find An Easier Way To Synthesize New Drug Candidates
    6/25/2010
    Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group.
  5. Life Scientists’ Guide For Solving Optimization Problems Now Available From NAG
    6/24/2010
    Worldwide life scientists seeking the most appropriate way to solve difficult optimization problems common to most research within the life sciences can get easy to follow step-by-step instructions on how to select the best-suited local or global optimization routines, from the Numerical Algorithms Group (NAG) Library, by making use of the Decision Trees for optimization.
  6. Sparta Systems Announces On-Demand White Papers And Analyst Reports
    6/22/2010
    Founded in 1994, Sparta Systems, Inc. is the leading provider of enterprise quality management software. In addition to its U.S. operations, the company provides sales and services to Europe, Asia and Australia through its subsidiaries, Sparta Systems Europe, Ltd. and Sparta Systems Asia.
  7. Waters New ACQUITY UPLC H-Class Method Development System Takes Automation To Higher Level
    6/21/2010
    Waters Corporation (NYSE: WAT) today unveiled its new Waters(R) ACQUITY UPLC(R) H-Class Method Development System that automates liquid chromatography method development according to Quality-by-Design (QbD) guidelines to produce robust, fit-for-purpose methods in dramatically less time than traditional processes.
  8. Sparta Systems Unveils TrackWise Software Version 8
    6/17/2010
    Sparta Systems., Inc., the maker of TrackWise® software and the market leader in enterprise quality and compliance management solutions, recently announced the general availability of Version 8 of its TrackWise enterprise quality management solution (EQMS).
  9. O2h Continues To Support Senexis To Support Patent Filing Senexis Limited
    6/14/2010
    Executives from Senexis Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer's Disease.
  10. EPA Extends Asterand’s Role In ToxCast Program
    6/7/2010
    Asterand plc, a leading human-based solutions provider to pharmaceutical companies engaged in drug discovery research, recently announced that the United States Environmental Protection Agency (EPA) has extended its Phase II funding commitment to Asterand's subsidiary BioSeek LLC under the agency's ToxCast™ screening program.

First 1 2 3 4 5 6 7 8 9 10 10 (Last)